Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same period last year, marking the highest quarterly revenues to date [4][23] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [5] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [24] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching approximately 8,500 average patients on WAKIX [4][10] - The approval of WAKIX for the treatment of cataplexy in pediatric patients aged six years and older is expected to enhance market penetration [12] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [5] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, reflecting strong expectations for growth [25] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the next-generation pitolisant formulations, including pitolisant GR and pitolisant HD, targeting unique indications in orphan rare diseases [7][9] - The company is advancing a robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications, aiming for multiple catalysts over the next few years [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, supported by strong commercial execution and a clear growth strategy [9][28] - The company remains committed to defending its intellectual property and is optimistic about the potential for pediatric exclusivity for WAKIX [7][24] Other Important Information - Harmony ended Q4 2025 with approximately $882.5 million in cash equivalents and investments, providing financial flexibility for growth initiatives [23] - The company is expanding its field-based teams by nearly 20% to enhance market presence and support continued growth [11] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the timeline for the NDA submission for pitolisant GR? - The company is on track to submit the NDA for pitolisant GR in Q2 2026, with a target PDUFA date in Q1 2027 [52][53] Question: How is the company preparing for the pediatric cataplexy indication? - Management highlighted that the approval for pediatric cataplexy provides greater flexibility for healthcare providers and is expected to enhance the overall market opportunity for WAKIX [90][91] Question: What are the dynamics behind the increase in SG&A expenses in Q4? - The increase in expenses was primarily driven by R&D investments for ongoing Phase 3 studies and litigation-related costs [61][70]

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Event**: 44th JPM Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights - **Core Focus**: Central Nervous System (CNS) disorders, particularly narcolepsy and related conditions - **Product Highlight**: WAKIX, a treatment for narcolepsy, is on track to achieve blockbuster status in 2026 with projected net revenue exceeding $1 billion Core Points and Arguments 1. **Momentum and Growth**: Harmony enters 2026 with significant momentum driven by three key factors: WAKIX performance, a robust late-stage pipeline, and a strong financial profile [2][3] 2. **WAKIX Performance**: WAKIX has shown five years of consecutive growth and profitability, with 2025 net revenue reported at $868 million, exceeding guidance [9][41] 3. **Pipeline Development**: Five phase three programs are advancing towards distinct CNS indications, setting up multiple catalysts for growth in the coming years [2][24] 4. **Pitolisant Franchise Expansion**: The introduction of Pitolisant GR (gastro-resistant formulation) and Pitolisant HD (high-dose formulation) aims to address unmet patient needs and expand the franchise [4][13] 5. **Market Opportunity**: There are approximately 80,000 diagnosed narcolepsy patients in the US, with an additional 90,000 undiagnosed, indicating significant growth potential for WAKIX [10][42] 6. **Commercial Strategy**: Harmony has improved its commercial operations, achieving broad formulary access (80% of lives covered) and enhancing patient support systems [11][27] 7. **Regulatory Milestones**: Anticipated NDA submission for Pitolisant GR in Q2 2026, with a PDUFA date expected in Q1 2027 [30][37] 8. **Financial Health**: Harmony maintains a strong balance sheet with over $770 million in cash, allowing for continued investment in pipeline development and business growth [44][45] Additional Important Insights - **Patient-Centric Approach**: The company emphasizes the importance of addressing patient needs, particularly in narcolepsy and related disorders, through innovative product formulations [4][14] - **Unique Product Profiles**: The differentiated profiles of Pitolisant formulations are expected to enhance clinical utility and market competitiveness [6][39] - **Future Catalysts**: Anticipated data readouts from ongoing trials in 2027 and 2028 for various CNS indications, including Prader-Willi syndrome and epilepsy programs [21][20] - **Business Development Focus**: Harmony is actively seeking strategic opportunities to expand its portfolio in the CNS space, particularly in orphan and rare diseases [44][45] This summary encapsulates the key points discussed during the conference, highlighting Harmony Biosciences' strategic direction, product pipeline, and market opportunities within the CNS industry.